Brain

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference

Company highlights ongoing clinical developments in traumatic brain injury (TBI) therapeutics and non-invasive cancer screening, sparking key vendor collaboration discussions....

RFU Neuroscientist Awarded $2.3 Million NIH Grant to Fund Ground-Breaking Research on Covid-19’s Impact on Adolescent Brains

Nicole Ferrara, PhD, will investigate how social deprivation alters amygdala development and social behavior during adolescenceNORTH CHICAGO, Ill., Sept. 24,...

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to KaziaSYDNEY, Sept. 22, 2026 /PRNewswire/ --...

error: Content is protected !!